GlassScriptPhysician profile
Earic R Bonner
NPI 1548526411
$7,823.49
in general payments reported to CMS, 2019-2025
29 companies · $184 in 2025
The $184 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,359 · 2020: $2,577 · 2021: $1,007 · 2022: $1,204 · 2023: $938 · 2024: $554 · 2025: $184.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,676.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,676.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,823.20 | 2019-2024 | Farxiga |
| Novo Nordisk INC | $1,322.54 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Sanofi-Aventis U.S. LLC | $764.27 | 2019-2022 | |
| Lilly USA, LLC | $658.81 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $576.69 | 2019-2024 | Jardiance |
| Amgen INC. | $403.03 | 2019-2024 | Repatha, Otezla |
| Novartis Pharmaceuticals Corporation | $303.71 | 2019-2025 | |
| Pfizer INC. | $283.21 | 2019-2024 | |
| Janssen Pharmaceuticals, INC | $254.32 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $234.20 | 2019-2023 | Verquvo, Belsomra, Steglatro |
| Abbott Laboratories | $149.84 | 2021-2023 | Freestyle Libre 2 |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $133.33 | 2021 | |
| Xeris Pharmaceuticals, INC. | $129.00 | 2022-2023 | Gvoke Hypopen |
| Grifols USA, LLC | $126.61 | 2019-2020 | |
| Glaxosmithkline, LLC. | $103.07 | 2020-2023 | Shingrix, Trelegy Ellipta |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $94.17 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $68.46 | 2020-2023 | Eliquis |
| Corcept Therapeutics | $68.03 | 2025 | Korlym |
| Dexcom, INC. | $57.30 | 2022-2025 | Dexcom G6 Transmitter |
| Axsome Therapeutics, INC. | $54.38 | 2023 | Auvelity |
| Neurocrine Biosciences, INC. | $48.57 | 2022 | |
| Allergan, INC. | $39.03 | 2019-2020 | |
| Idorsia Pharmaceuticals US INC | $35.25 | 2023 | Quviviq |
| Viiv Healthcare Company | $21.96 | 2023 | Apretude |
| Teva Pharmaceuticals USA, INC. | $16.31 | 2020 | |
| Azurity Pharmaceuticals, INC. | $15.98 | 2024 | Horizant |
| Phathom Pharmaceuticals, INC. | $14.66 | 2025 | Voquezna |
| Mylan Specialty L.P. | $13.36 | 2021 | |
| Cequr Corporation | $10.20 | 2024 | Cequr Simplicity |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Earic Bonner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.